What is your clinical experience with long-acting injectable agents for HIV?
- Can you share strategies to prevent treatment-emergent resistance from developing?
- What are the pros and cons of starting with therapies that can avoid development of multi-drug resistant HIV?

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

HIV Treatment Clinical Experiences

EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP: 2.Evolving Treatment Practices and Guidelines for HIV

EP: 3.Key Clinical Considerations in HIV Treatment Decisions

EP: 4.HIV Treatment: Discussing Adverse Events with Patients

EP: 5.Importance of Starting HIV Treatment Early

EP: 6.Treatment Resistance in HIV

EP: 7.HIV Drug Resistance Testing Practices and Patient Education

EP: 8.Managing Suboptimal Adherence to HIV Medications

EP: 9.HIV Treatment Clinical Experiences

EP: 10.Addressing Suboptimal Treatment Response in HIV

EP: 11.Current HIV Treatment Regimens

EP: 12.Rapid Treatment Initiation in HIV

EP: 13.Switching Therapies for Patients with HIV and History of Resistance

EP: 14.Resources Available for Patients with HIV Drug Resistance

EP: 15.Factors that Inform Treatment Selection in HIV

EP: 16.Switching Therapies in HIV

EP: 17.Restarting Therapy in Patients with HIV

EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV

EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP: 22.HIV: Treating Patients with Viral Mutations

Newsletter